• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19

byMinjee Kim
December 23, 2021
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The use of COVID-19 convalescent plasma did not benefit patients hospitalized with COVID-19, assessed using the World Health Organization 11-point Ordinal Scale for Clinical Improvement.

2. However, the subgroup analyses found COVID-19 convalescent plasma to be beneficial in patients enrolled from April to June 2020, a period when most participants received high-titer COVID-19 convalescent plasma instead of corticosteroids and remdesivir.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The use of convalescent plasma in prior pandemics as well as its biological plausibility has prompted the role for COVID-19 convalescent plasma (CCP) use in patients hospitalized with COVID-19. This randomized clinical trial assessed the safety and efficacy of CCP compared to placebo in hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen. The primary endpoint was patient scores on the 11-point World Health Organization (WHO) Ordinal Scale for Clinical Improvement on day 14 where secondary endpoint was determined on day 28. An exploratory subgroup analyses was performed with respect to age, baseline WHO score, concomitant medications, symptom duration, CCP SARS-CoV-2 titer, baseline SARS-CoV-2 serostatus, and enrollment quarter. Among 941 hospitalized patients with COVID-19 requiring noninvasive oxygen supplementation, the use of CCP did not meet the prespecified definition of CCP efficacy (cumulative adjusted odds ratio [cOR] <1 and a clinically meaningful effect as cOR <0.8). However, the subgroup analyses found CCP to be beneficial in patients enrolled from April to June 2020, a period when most participants received high-titer CCP instead of corticosteroids and remdesivir. This supports the theory that convalescent plasma may be a more feasible treatment option during earlier stages of a pandemic or when other therapies are not yet in use or available. A limitation of this study was that the primary endpoint set at day 14 was likely too early for COVID-19, a virus known to have a more prolonged course and thus, highlighting the importance of the findings for the secondary endpoint at day 28.

Click to read the study in JAMA Internal Medicine

Relevant Reading: Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study

RELATED REPORTS

Unvaccinated status increases risk of long COVID symptoms

Combined visual-olfactory training for COVID-19 resultant olfactory loss

2 Minute Medicine Rewind January 23, 2023

In-Depth [randomized clinical trial]: This double-blind, placebo-controlled trial, CONTAIN COVID-19, included 941 (556 men [59.1%]; median age [IQR], 63 [52-73] years; 373 [39.6%] Hispanic, 132 [14.0%] non-Hispanic Black) hospitalized adults with COVID-19 from 21 US hospitals between April 2020 to March 2021. Eligible patients were those hospitalized for 3 or less days or presented 7 or less days after symptom onset and required noninvasive oxygen supplementation, where 473 individuals were randomized to placebo (normal saline) and 468 to CCP. For the primary endpoint, the cOR adjusted for site, baseline risk, WHO score, age, sex, and symptom duration was 0.94 (95% credible interval [CrI], 0.75-1.18) with posterior probability (P[cOR<1] = 72%). The cOR for the secondary adjusted outcome was 0.92 (95% CrI, 0.74-1.16; P[cOR<1] = 76%). Heterogeneity of treatment effect was observed through the exploratory subgroup analyses where on day 28, cORs were 0.72 (95%CrI, 0.46-1.13; P[cOR<1] = 93%) for participants enrolled from April to June 2020 and 0.65 (95%CrI, 0.41 to 1.02; P[cOR<1] = 97%) for those who did not receive remdesivir and corticosteroids. Adverse events were reported for 39 (8.2%) placebo patients and 44 (9.4%) patient receiving CCP (P = .57) and transfusion reactions occurred in 2 (0.4) placebo recipients and 8 (1.7) CCP recipients (P = .06).

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: convalescent plasmacorticosteroidsCOVID-19COVID-19 convalescent plasmaremdesivirSARS-CoV-2WHO 11-point Ordinal Scale for Clinical Improvement
Previous Post

Omega-3 fatty acid supplements did not reduce depression risk in adults compared to placebo

Next Post

Wellness Check: Addictions

RelatedReports

Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Unvaccinated status increases risk of long COVID symptoms

January 25, 2023
School nurses essential in design and implementation of school safety programs
Chronic Disease

Combined visual-olfactory training for COVID-19 resultant olfactory loss

January 23, 2023
Many new pediatric asthma cases attributable to obesity
Weekly Rewinds

2 Minute Medicine Rewind January 23, 2023

January 23, 2023
#VisualAbstract: Treatment with fluvoxamine does not improve time to sustained recovery in outpatients with mild to moderate COVID-19
StudyGraphics

#VisualAbstract: Treatment with fluvoxamine does not improve time to sustained recovery in outpatients with mild to moderate COVID-19

January 23, 2023
Next Post
Ultrasound enhances gastrointestinal absorption of drugs at low frequencies

Wellness Check: Addictions

#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa

#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Severe gastrointestinal involvement in children with SARS-CoV-2 infection and multisystem inflammatory syndrome

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options